Tarsus Pharmaceuticals(TARS) - 2024 Q2 - Quarterly Results

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $40.8 million in XDEMVY net product sales in the second quarter and $65.5 million year-to-date ® Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 ...